基于非酒精性脂肪性肝病机制及治疗的动物模型研究进展

陈艳珍; 陈成良; 田兴; 焦健

doi:10.3969/j.issn.1001-5256.2017.12.046

基于非酒精性脂肪性肝病机制及治疗的动物模型研究进展

DOI: 10.3969/j.issn.1001-5256.2017.12.046

吉林大学中日联谊医院消化内科

详细信息

中图分类号: R-332;R575.5
计量
- 文章访问数: 1391
- HTML全文浏览量: 58
- PDF下载量: 402
- 被引次数: 0
出版历程
- 收稿日期: 2017-08-08
- 出版日期: 2017-12-20

Research advances in animal models based on the pathogenesis and treatment of nonalcoholic fatty liver disease

Department of Gastroenterology, China-Japan Union Hospital of Jilin University

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)是以过量脂质在肝细胞内堆积为特征的连续疾病谱,可由单纯的肝脂肪变性发展为非酒精性脂肪性肝炎,并可进一步进展为肝纤维化、肝硬化、甚至肝细胞癌。动物模型可模拟不同病因以及NAFLD每个阶段的组织病理学和病理生理学改变,为了解NAFLD发病机制和治疗措施提供关键性的指导。目前尚缺乏能完整模仿疾病谱的理想动物模型,介绍了NAFLD及相关肝癌的最常用和最新的动物模型,并结合动物模型中NAFLD的实验性发病机制总结了可能的治疗靶点,希望能为进一步探讨NAFLD发病机制和治疗提供依据。
- 非酒精性脂肪性肝病 /
- 模型,动物 /
- 综述
Abstract: Nonalcoholic fatty liver disease ( NAFLD) is a continuous disease spectrum characterized by the accumulation of excessive lipid in hepatocytes. Simple hepatic steatosis may progress to NAFLD and even liver fibrosis, liver cirrhosis, and finally hepatocellular carcinoma.Animal models can simulate different causes and histopathological and pathophysiological changes in each stage of NAFLD and thus provide critical guidance for understanding the pathogenesis of NAFLD and selecting therapeutic measures. At present, there are still no ideal animal models that can simulate the whole disease spectrum. This article introduces the most frequently used and recently developed animal models for NAFLD and NAFLD-induced liver cancer and summarizes possible therapeutic targets with reference to the experimental pathogenesis of NAFLD in animal models, in order to provide a basis for further research on the pathogenesis and treatment of NAFLD.
- nonalcoholic fatty liver disease /
- model animal /
- review

HTML全文

参考文献(45)

[1]RATZIU V, GIRAL P, CHARLOTTE F, et al.Liver fibrosis in overweigh patients[J].Gastroenterology, 2000, 118 (6) :1117-1123.

[2]GAGGINI M, MORELLI M, BUZZIGOLI E, et al.Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease[J].Nutrients, 2013, 5 (5) :1544-1560

[3]WREE A, BRODERICK L, CANBAY A, et al.From NAFLD to NASH to cirrhosis new insights into disease mechanisms[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :627-636.

[4]DOWMAN JK, TOMLINSON JW, NEWSOME PN.Pathogenesis of non-alcoholic fatty liver disease[J].QJM, 2010, 103 (2) :71-83.

[5]STARLEY BQ, CALCAGNO CJ, HARRISON SA.Nonalcoholic fatty liver disease and hepatocellular carcinoma:a weighty connection[J].Hepatology, 2010, 51 (5) :1820-1832.

[6]ANSTEE QM, GOLDIN RD.Mouse models in non-alcoholic fatty liver disease and steatohepatitis research[J].Int J Exp Pathol, 2006, 87 (1) :1-16.

[7]NIETO-VAZQUEZ I, FERNNDEZ-VELEDO S, KRMER DK, et al.Insulin resistance associated to obesity:the link TNF-alpha[J].Arch Physiol Biochem, 2008, 114 (3) :183-194.

[8]LIEBER CS, LEO MA, MAK KM, et al.Model of nonalcoholic steatohepatitis[J].A J Clin Nutr, 2004, 79 (3) :502-509.

[9]ECCLESTON HB, ANDRINGA KK, BETANCOUNRT AM, et al.Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxidebioavailability, and modifies the mitochondrial proteome in mice[J].Antioxid Redox Signal, 2011, 15 (2) :447-459.

[10]LAU JK, ZHANG X, YU J.Animal models of non-alcoholic fatty liver disease:current perspectives and recent advances[J].JPathol, 2017, 241 (1) :36-44.

[11]FAKHOURY-SAYEGH N, TRAK-SMAYRA V, KHAZZAKAA, et al.Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets[J].Nutr Res Pract, 2015, 9 (4) :350-357.

[12]JIN J, VALANEJAD L, NGUYEN TP, et al.Activation of CDK4 triggers development of non-alcoholic fatty liver disease[J].Cell Rep, 2016, 16 (3) :744-756.

[13]XIA SF, LE GW, WANG P, et al.Regressive effect of myricetin on hepatic steatosis in mice fed a high-fat diet[J].Nutrients, 2016, 8 (12) :799.

[14]TRAK-SMAYRA V, PARADIA V, MASSART J, et al.Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet[J].Int J Exp Pathol, 2011, 92 (6) :413-421.

[15]YANG SQ, LIN HZ, LANE MD, et al.Obesity increases sensitivity to endotoxin liver injury:implications for the pathogenesis of steatohepatitis[J].Proc Natl Acad Sci U S A, 1997, 94 (6) :2557-2562.

[16]SAHAI A, MALLADI P, PAN X, et al.Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis:role of short-form leptin receptors and osteopontin[J].Am J Physiol Gastrointest Liver Physiol, 2004, 287 (5) :g1035-g1043.

[17]PAZ-FILHO G, MASTROARDI C, DELIBASI T, et al.Congenital leptin deficiency:diagnosis and effects of leptin replacement therapy[J].Arq Bras Endocrinol Metabol, 2010, 54 (8) :690-697.

[18]LI Y, ZALZALA M, JADHAV K, et al.Carboxylesterase 2 prevents liver by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice[J].Hepatology, 2016, 63 (6) :1860-1874.

[19]FARRELL GC, LARTER CZ.Nonalcoholic fatty liver disease:from steatosis to cirrhosis[J].Hepatology, 2006, 43 (2 Suppl 1) :s99-s112.

[20]GANZ M, SZABO G.Immune and inflammatory pathways in NASH[J].Hepatol Int, 2013, 7 (suppl 2) :771-781.

[21]TAKAHASHI Y, SOEJIMA Y, FUKUSATO T.Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].World J Gastroenterol, 2012, 18 (19) :2300-2308.

[22]DAY CP, JAMES OF.Steatohepatitis:a tale of two‘hits’?[J].Gastroenterology, 1998, 114 (4) :842-845.

[23]TILG H, MOSCHEN AR.Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis[J].Hepatology, 2010, 52 (5) :1836-1846.

[24]MEDINA J, FERNANDEZ-SALAZAR LI, GARCIA-BUEY L, et al.Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis[J].Diabetes Care, 2004, 27 (8) :2057-2066.

[25]CORBIN KD, ZEISEL SH.Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression[J].Curr Opin Gastroenterol, 2012, 28 (2) :159-165.

[26]YAMADA T, OBATA A, KASHIWAGI Y, et al.Gd-EOB-DT-PA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice[J].Magn Reson Imaging, 2016, 34 (6) :724-729.

[27]MACHADO MV, MICHELOTTI GA, XIE G, et al.Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease[J].PLo S One, 2015, 10 (6) :e0127991.

[28]YAMAMOTO T, NAKADE Y, YAMAUCHI T, et al.Glucagonlike peptide analogue prevents nonalcoholic steatohepatitis in nonobese mice[J].World J Gastroenterol, 2016, 22 (8) :2512-2523.

[29]RINELLA ME, GREEN RM.The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance[J].J Hepatol, 2004, 40 (1) :47-51.

[30]KANURI G, BERGHEIM I.In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD) [J].Int J Mol Sci, 2013, 14 (6) :11963-11980.

[31]SUBRAMANIAN S, GOODSPEED L, WANG S, et al.Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice[J].J Lipid Res, 2011, 52 (9) :1626-1635.

[32]SAVARD C, TARATAGLIONE EV, KUVER R, et al.Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis[J].Hepatology, 2013, 57 (1) :81-92.

[33]KOHLI R, KIRBY M, XANTHAKOS SA, et al.High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis[J].Hepatology, 2010, 52 (3) :934-944.

[34]ZHANG X, HAN J, MAN K, et al.CXC chemokine receptor 3promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy[J].J Hepatol, 2016, 64 (1) :160-170.

[35]BELL-ANDERSON KS, AOUAD L, WILLIAMS H, et al.Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice[J].Int J Obes (Lond) , 2011, 35 (12) :1539-1548.

[36]FARRELL GC, MRIDHA AR, YEH MM, et al.Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype[J].Liver Int, 2014, 34 (7) :1084-1093.

[37]HANDA P, MORGAN-STEVENSON V, MALIKEN BD, et al.I-ron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice[J].Am J Physiol Gastrointest Liver Physiol, 2016, 310 (2) :g117-g127.

[38]BRUNT EM, TINIAKOS DG.Histopathology of nonalcoholic fatty liver disease[J].World J Gastroenterol, 2010, 16 (42) :5286-5296.

[39]HEINDRYCKX F, COLLE I, van VLIERBERGHE H.Experimental mouse models for hepatocellular carcinoma research[J].Int JExp Pathol, 2009, 90 (4) :367-386.

[40]WOLF MJ, ADILI A, PIOTROWITZ K, et al.Metabolic activation of intrahepatic CD8+T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes[J].Cancer Cell, 2014, 26 (4) :549-564.

[41]de MINICIS S, AGOSTINELLI L, RYCHLICKI C, et al.HCC development is associated to peripheral insulin resistance in a mouse model of NASH[J].PLo S One, 2014, 9 (5) :e97136.

[42]ASGHARPOUR A, CAZANAVE SC, PACANA T, et al.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J].J Hepatol, 2016, 65 (3) :579-588.

[43]FUJII M, SHIBAZAKI Y, WAKAMATSU K, et al.A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma[J].Med Mol Morphol, 2013, 46 (3) :141-152.

[44]WATANABE S, HORIE Y, KATAOKA E, et al.Non-alcoholic steatohepatitis and hepatocellular carcinoma:lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN) -deficient mice[J].J Gastroenterol Hepatol, 2007, 22 (suppl 1) :s96-s100.

[45]SHEN J, TSOI H, LIANG Q, et al.Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma[J].Oncogene, 2016, 35 (49) :6271-6280.

施引文献

资源附件(0)

访问统计